scholarly journals Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma

Theranostics ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 4323-4333 ◽  
Author(s):  
Huan Lu ◽  
Yuan Liang ◽  
Bao Guan ◽  
Yue Shi ◽  
Yanqing Gong ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Aristolochic Acid ◽  
Low Risk ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract ◽  
Mutational Signature

scholarly journals Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes

2013 ◽  
Vol 133 (1) ◽  
pp. 14-20 ◽  
Author(s):  
Chung-Hsin Chen ◽  
Kathleen G. Dickman ◽  
Chao-Yuan Huang ◽  
Masaaki Moriya ◽  
Chia-Tung Shun ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Clinical Characteristics ◽  
Aristolochic Acid ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract

scholarly journals Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma

Theranostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 5578-5580
Author(s):  
Arnoud Boot ◽  
Nanhai Jiang ◽  
Steven G. Rozen
Keyword(s):  
Urothelial Carcinoma ◽  
Aristolochic Acid ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract

scholarly journals Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact?

2016 ◽  
Vol 5 (5) ◽  
pp. 648-654
Author(s):  
Pierre Colin ◽  
Thomas Seisen ◽  
Romain Mathieu ◽  
Sharohkh F. Shariat ◽  
Morgan Rouprêt
Keyword(s):  
Lynch Syndrome ◽  
Urothelial Carcinoma ◽  
Aristolochic Acid ◽  
Clinical Impact ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract

234 Identification and clinical outcomes of aristolochic acid-induced upper tract urothelial carcinoma

2013 ◽  
Vol 12 (1) ◽  
pp. e234-e235
Author(s):  
C.H. Chen ◽  
K.G. Dickman ◽  
C.Y. Huang ◽  
C.T. Shun ◽  
A.P. Grollman ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Clinical Outcomes ◽  
Aristolochic Acid ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract

scholarly journals Role of Ureteroscopy in Treatment of Upper Tract Urothelial Carcinoma

2021 ◽  
Vol 22 (10) ◽  
Author(s):  
Jeremy Ng Chieng Hin ◽  
Dinul Hettiarachchilage ◽  
Paul Gravestock ◽  
Bhavan Rai ◽  
Bhaskar K. Somani ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Upper Urinary Tract ◽  
Low Risk ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract ◽  
Management Algorithm ◽  
Technological Advances ◽  
Biodegradable Stents ◽  
Intracavitary Therapy

Abstract Purpose of Review Upper tract urothelial carcinoma (UTUC) is uncommon accounting for less than 10% of all urothelial tumours. Ureteroscopic management (URS) is the first line treatment for low-risk disease and has been increasingly utilised due to technological advances and increasing surgical experience. This review looks at patient outcomes relating to URS, emerging technologies and the role of adjuvant intracavitary therapy in the management of UTUC. Recent Findings URS has firmly established itself in the management algorithm for UTUC, and a good body of evidence supports its use for low-risk disease, wherein oncological outcomes are comparable to traditional nephroureterectomy (RNU). Larger tumours can now be managed using URS with a lower morbidity than radical surgery, though with higher associated local recurrence rate and risk of progression to RNU, and as a result, patient selection and close surveillance remains key. There is limited evidence for adjuvant intracavitary therapy (Mitomycin C or BCG) in UTUC although the development of novel polymers and biodegradable stents may improve drug delivery to the upper urinary tract. Summary URS has a clearly defined role in low-risk UTUC, and its use in larger tumours appears to be appropriate in a selected cohort of patients. The efficacy of adjuvant intracavitary therapy is as of yet undetermined, though developments in delivery techniques are promising. Likewise further developments of laser technology are anticipated to further expand the role of URS.

scholarly journals Mutational signatures in upper tract urothelial carcinoma define etiologically distinct subtypes with prognostic relevance

2019 ◽  
Author(s):  
Xuesong Li ◽  
Huan Lu ◽  
Bao Guan ◽  
Zhengzheng Xu ◽  
Yue Shi ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Clinical Outcomes ◽  
Genome Sequencing ◽  
Upper Tract Urothelial Carcinoma ◽  
Herbal Remedies ◽  
Mutational Signatures ◽  
Upper Tract ◽  
Mutational Signature ◽  
Prognostic Relevance ◽  
Increased Risk

AbstractParts of East Asia have a very high upper tract urothelial carcinoma (UTUC) prevalence, and an etiological link between the medicinal use of herbs containing aristolochic acid (AA) and UTUC has been established. The mutational signature of AA, which is characterized by a particular pattern of A:T to T:A transversions, can be detected by genome sequencing. Thus, integrating mutational signatures analysis with clinicopathological data may be a crucial step toward personalized treatment strategies for the disease. Therefore, we performed whole-genome sequencing (WGS) of 90 UTUC patients from China. Mutational signature analysis via nonnegative matrix factorization method defined three etiologically distinct subtypes with prognostic relevance: (i) AA, the typical AA mutational signature characterized by signature 22, had the highest tumor mutation burden, the best clinical outcomes; (ii) Age, an age-related group featured by signatures 1 and 5, had the lowest weighted genome instability index score, the worst clinical outcomes; and (iii) DSB, signature with deficiencies in DNA double strand break-repair featured by signatures 3, the intermediate clinical outcomes. Additionally, the distinct AA subtype was associated with AA exposure, the highest number of predicted neoantigens and heavier lymphocytes infiltrating. Thus, it may be good candidate for immune checkpoint blockade therapy. Notably, we showed AA-mutational signature was also identified in histologically “normal” urothelial cells. Thus, non-invasive urine test based on the AA-mutational signature could take advantage of this “field effect” to screen individuals at increased risk of recurrence due to exposure to herbal remedies containing the carcinogen AA. Collectively, the findings here may accelerate the development of novel prognostic markers and personalized therapeutic approaches for UTUC patients in China.

scholarly journals Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients

2018 ◽  
Vol Volume 10 ◽  
pp. 6627-6639 ◽  
Author(s):  
Gengyan Xiong ◽  
Lin Yao ◽  
Peng Hong ◽  
Li Yang ◽  
Weimin Ci ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Aristolochic Acid ◽  
Upper Tract Urothelial Carcinoma ◽  
Upper Tract
Sign in / Sign up

Export Citation Format

Share Document